CSF IL-6 and MCP-1 levels distinguish neuropsychiatric involvement in systemic lupus erythematosus patientsBlood and fluid markers help identify lupus brain involvement

Frontiers in Medicine Published October 2, 2026 Study authors: Carolina Muñoz-Grajales, Sara Duaibes, Alan Cheng, Yasmin Nariman, Melanie Anderson, Dennisse Bonill… DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that CSF IL-6 and MCP-1 distinguish NPSLE from non-NPSLE, but lack specificity and ease of collection.

This meta-analysis synthesized data from 93 studies to identify biomarkers that distinguish patients with systemic lupus erythematosus (SLE) who have neuropsychiatric involvement (NPSLE) from those without. The analysis focused on both cerebrospinal fluid (CSF) and serum analytes to determine their diagnostic potential.

Key findings include significantly higher levels of CSF IL-6 (Hedges' g 0.81) and CSF MCP-1 (Hedges' g 0.66) in patients with NPSLE compared to those without. Additionally, the presence of specific serum autoantibodies was associated with higher odds of NPSLE: anti-ribosomal P (OR 2.68; 95% CI 2.03-3.53), anti-NR2/NMDAR (OR 2.09; 95% CI 1.07-4.06), and IgG anticardiolipin (OR 2.36; 95% CI 1.56-3.59).

Several limitations were noted, including the use of small and heterogeneous studies for most promising biomarkers, as well as inconsistent assays, cutoffs, and case definitions. While CSF markers show potential for differentiation, they are not easily obtainable in routine practice and lack specificity. Serum autoantibodies provide only modest, phenotype-dependent diagnostic performance. Clinical utility is currently limited by these factors.

How this fits prior evidence

This meta-analysis addresses a gap in identifying specific biomarkers for neuropsychiatric involvement in systemic lupus erythematosus. While previous evidence confirmed that SLE is associated with a more than twofold increased risk of stroke, this study focuses on the biochemical differentiation of neuropsychiatric involvement. The findings regarding serum autoantibodies provide additional data on the heterogeneity of SLE manifestations, though they are noted to have modest diagnostic performance.

Living with systemic lupus erythematosus (SLE) can be unpredictable, especially when it affects the brain and nervous system. This condition, known as neuropsychiatric lupus, can be difficult to pinpoint early. Researchers analyzed 93 studies to find markers that could help doctors tell the difference between patients with and without these neurological symptoms.

The review found that certain markers in the cerebrospinal fluid (the fluid around the brain and spine) were higher in patients with brain involvement. Specifically, markers called IL-6 and MCP-1 showed a clear increase. While these markers help distinguish the two groups, they are not easy to collect during routine checkups.

Blood tests also showed some promise. Patients with certain antibodies, such as anti-ribosomal P, anti-NR2/NMDAR, and IgG anticardiolipin, had higher odds of having brain involvement. However, these blood markers only show modest results and vary depending on the patient's specific symptoms. Because the original studies were small and used different testing methods, the evidence is still considered fragmented.

What this means for you:

Specific markers in spinal fluid and blood can help identify lupus that affects the brain, though results vary.

Common questions

What markers were found in spinal fluid?

The study found that IL-6 and MCP-1 levels were higher in patients with neuropsychiatric lupus compared to those without it. While these markers help distinguish between the two groups, they are not specific for the condition and are difficult to collect during routine medical practice.

Can blood tests help identify brain involvement in lupus?

Yes, certain antibodies in the blood can show a link. Patients positive for anti-ribosomal P, anti-NR2/NMDAR, or IgG anticardiolipin had higher odds of having neuropsychiatric involvement. However, these blood markers only show modest results that depend on the patient's specific symptoms.

How reliable are these new findings?

The evidence is currently fragmented. Because the original studies were small and used different testing methods and definitions, the results are not yet definitive. You should talk to your doctor about how these markers might apply to your specific diagnosis.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedOct 2026

View Original Abstract ↓

This study aims to evaluate biomarkers that discriminate systemic lupus erythematosus patients with and without neuropsychiatric involvement. We searched MEDLINE, Embase, and CENTRAL (inception—March 2024) for studies of blood or cerebrospinal fluid (CSF) analytes in neuropsychiatric systemic lupus erythematosus (NPSLE). Random-effects meta-analyses were conducted for analyte-biofluid pairs with ≥5 independent studies; the remaining data were synthesized narratively. A total of 93 studies were included. Few analyte–biofluid combinations met the criteria for meta-analysis, and most promising biomarkers (intrathecal inflammation, neuronal injury, and reduced neuroprotection) were assessed in only small, heterogeneous studies. The meta-analyses showed higher CSF IL-6 and MCP-1 in NPSLE than non-NPSLE SLE (Hedges’ g 0.81 and 0.66, respectively), a smaller heterogeneous effect for IL-8, and two- to threefold higher odds of NPSLE in patients positive for serum anti-ribosomal P (OR 2.68, 95% CI 2.03–3.53), anti-NR2/NMDAR (2.09, 1.07–4.06), and IgG anticardiolipin (2.36, 1.56–3.59) antibodies. Compared with non-SLE controls, NPSLE generally showed higher CSF soluble mediators than healthy or non-inflammatory neurological comparators, but the levels in CNS infections were often similar or higher. CSF markers of intrathecal inflammation, neuronal injury, and reduced neuroprotection distinguish NPSLE from non-NPSLE SLE but are neither specific for NPSLE nor easily obtainable in routine practice. Classical serum autoantibodies (anti-ribosomal P, anti-NR2, and antiphospholipid antibodies) show modest, phenotype-dependent diagnostic performance. Evidence remains fragmented, with heterogeneous assays, cutoffs, and case definitions, underscoring the need for harmonized multicenter studies to identify robust diagnostic, evaluative, and prognostic biomarkers for overall and manifestation-specific NPSLE.

CSF IL-6 and MCP-1 levels distinguish neuropsychiatric involvement in systemic lupus erythematosus patientsBlood and fluid markers help identify lupus brain involvement

How this fits prior evidence

Common questions

Study Details

Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients

Your Blood May Signal a Deadly Clotting Crisis Before It Strikes

Clinical research that matters. Delivered to your inbox.

CSF IL-6 and MCP-1 levels distinguish neuropsychiatric involvement in systemic lupus erythematosus patientsBlood and fluid markers help identify lupus brain involvement

How this fits prior evidence

Common questions

More on Systemic Lupus Erythematosus

Study Details

Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients

Your Blood May Signal a Deadly Clotting Crisis Before It Strikes

Clinical research that matters. Delivered to your inbox.

Related in Hematology

From Other Specialties